Checking Potassium Levels With an AI-Assisted ECG Device in Chronic Kidney Disease
Tests a mobile AI heart-tracing device to check potassium in adults with advanced kidney disease.
Plain-language title generated from the registry record
Registry title: Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5
Key facts
- Where
- Beijing, Nanning, and Wuhan, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate-to-advanced chronic kidney disease (stages 3b-5) who see their kidney clinic regularly and can use a mobile ECG device to check potassium.
- Age
- 18 Years to 99 Years
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease stages 3b-5 (eGFR: 10 - <45 ml/min/1.73m²).
- Earlier treatment
- Must have had at least 1 visit per 3 months at the study site in the year before enrollment. Must not already be on kidney replacement therapy.
Main reasons for not taking part
- Already on kidney replacement therapy, or will start it within 6 months
- Unwilling or unable to monitor potassium with the study device
- Has an implanted heart pacemaker
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06901960, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaNot yet recruiting
- Hubei Provincial Hospital of TCMWuhan, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT06901960
- Record updated
- 17 September 2025
- Original description
The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to optimal management of hyperkalemia (the reduced occurrence of serum potassium ≥ 5.0 mmol/L during 6 months of follow-up). It will also learn about the adherence of using a mobile monitoring device.Read full original descriptionShow less
Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5 to Reduce Rate of Hyperkalemia - a Practical Randomized Clinical Trial
The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to optimal management of hyperkalemia (the reduced occurrence of serum potassium ≥ 5.0 mmol/L during 6 months of follow-up). It will also learn about the adherence of using a mobile monitoring device.
Participants will:
* Measure their serum potassium using an AI-enhanced point-of-care ECG device at least twice per week * Receive health education prompts to reduce intake of potassium rich foods if their electrocardiogram device measured serum potassium is abnormal * Receive alerts to visit nephrology clinic if their electrocardiogram device measured serum potassium is continuously abnormal
Inclusion: Patients with chronic kidney disease stages 3b-5 (eGFR: 10 - <45 ml/min/1.73m²); Patients with regular visits in the study sites to manage their chronic kidney disease (≥ 1 visit per 3 months during the past year before enrollment); Willingness to participate in the study with signed informed consent.
Exclusion: Patients already under kidney replacement therapy or will receive kidney replacement therapy in 6 months; Patients with heart pacemaker implanted; Unwillingness or without the ability to monitor hyperkalemia using the study device.